bluebird bio (BLUE) Stock Rating Reaffirmed by Oppenheimer
Other equities research analysts have also recently issued research reports about the stock. Maxim Group reiterated a buy rating and issued a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Morgan Stanley cut shares of bluebird bio from an equal weight rating to an underweight rating and set a $105.00 target price for the company. in a research note on Monday, October 2nd. Wells Fargo & Co reiterated an outperform rating and issued a $242.00 target price (up previously from $190.00) on shares of bluebird bio in a research note on Tuesday, December 12th. CIBC began coverage on shares of bluebird bio in a research note on Thursday, December 21st. They issued a market perform rating for the company. Finally, Barclays increased their target price on shares of bluebird bio from $151.00 to $162.00 and gave the company an overweight rating in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have assigned a buy rating to the company. bluebird bio has an average rating of Hold and an average target price of $157.45.
Shares of bluebird bio (NASDAQ:BLUE) traded up $2.45 during trading hours on Tuesday, hitting $171.95. The stock had a trading volume of 638,200 shares, compared to its average volume of 1,040,000. The firm has a market capitalization of $7,880.00, a P/E ratio of -24.53 and a beta of 2.08. bluebird bio has a 12 month low of $63.10 and a 12 month high of $222.03.
In other bluebird bio news, CEO Nick Leschly sold 10,823 shares of the firm’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $145.05, for a total transaction of $1,569,876.15. Following the completion of the transaction, the chief executive officer now owns 262,409 shares in the company, valued at $38,062,425.45. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Vachon sold 7,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $216.64, for a total transaction of $1,516,480.00. Following the transaction, the director now owns 8,000 shares of the company’s stock, valued at approximately $1,733,120. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 222,268 shares of company stock valued at $38,896,707. Corporate insiders own 3.90% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. QS Investors LLC raised its stake in shares of bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 500 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 813 shares during the last quarter. Biondo Investment Advisors LLC bought a new position in shares of bluebird bio in the third quarter valued at approximately $203,000. SG Americas Securities LLC raised its stake in shares of bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 295 shares during the last quarter. Finally, Fairfield Bush & CO. bought a new position in shares of bluebird bio in the second quarter valued at approximately $210,000.
ILLEGAL ACTIVITY WARNING: “bluebird bio (BLUE) Stock Rating Reaffirmed by Oppenheimer” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/10/bluebird-bio-blue-stock-rating-reaffirmed-by-oppenheimer.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.